Pancreatic Cancer Research

ResearcherFondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoActive in the last 2 years

Gianluca Tomasello

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-0941-8547; OpenAlex author ID A5103727229. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 4 papers · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 13

  1. Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes. Co-author DOI 10.1016/j.ctrv.2026.103170↗
  2. Upfront Chemotherapy Versus Immediate Surgery for Operable Pancreatic Cancer: An Umbrella Review of Meta-Analyses. Co-author DOI 10.3390/cancers18091344↗
  3. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Co-author DOI 10.1016/j.dld.2025.11.007↗
  4. Comparative Efficacy of 21 Treatment Strategies for Resectable Pancreatic Cancer: A Network Meta-Analysis. Co-author DOI 10.3390/cancers16183203↗
  5. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis. Co-author DOI 10.1186/s12876-023-02853-w↗
  6. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. Co-author DOI 10.1016/j.radonc.2021.09.001↗
  7. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Co-author DOI 10.3390/cancers13174396↗
  8. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. Co-author DOI 10.21037/jgo.2018.12.08↗
  9. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and … Co-author DOI 10.3390/cancers11040484↗
  10. Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. Last author DOI 10.3390/cancers11040550↗
  11. Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? Co-author DOI 10.3390/cancers11081095↗
  12. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.ejca.2017.05.025↗
  13. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. First author DOI 10.1016/j.hpb.2017.07.005↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fausto Petrelli · 12 shared papers, 2017–2026 · strength 1.77
  2. Michele Ghidini · 11 shared papers, 2017–2026 · strength 1.69
  3. Lorenzo Dottorini · 3 shared papers, 2024–2026 · strength 0.80
  4. Shelize Sadrudin Khakoo · 3 shared papers, 2019–2023 · strength 0.41
  5. Alberto Zaniboni · 2 shared papers, 2019–2026 · strength 0.39
  6. Gianpaolo Balzano · 1 shared paper, 2026 · strength 0.30
  7. Sara Cherri · 1 shared paper, 2026 · strength 0.29
  8. Ester Oneda · 1 shared paper, 2026 · strength 0.29
  9. Sandro Barni · 3 shared papers, 2017–2019 · strength 0.26
  10. Federico Nichetti · 2 shared papers, 2019–2025 · strength 0.24
  11. Monica Niger · 2 shared papers, 2019–2025 · strength 0.24
  12. Angelica Petrillo · 2 shared papers, 2019–2021 · strength 0.23
  13. Francesco Leone · 1 shared paper, 2025 · strength 0.16
  14. Caterina Vivaldi · 1 shared paper, 2025 · strength 0.16
  15. Elisa Giommoni · 1 shared paper, 2025 · strength 0.16
  16. Emanuela Dell’Aquila · 1 shared paper, 2025 · strength 0.16
  17. Silvia Bozzarelli · 1 shared paper, 2025 · strength 0.16
  18. Francesca Bergamo · 1 shared paper, 2025 · strength 0.16
  19. Ingrid Garajová · 1 shared paper, 2025 · strength 0.16
  20. Ilario Giovanni Rapposelli · 1 shared paper, 2025 · strength 0.16
  21. Carolina Sciortino · 1 shared paper, 2025 · strength 0.16
  22. Lisa Salvatore · 1 shared paper, 2025 · strength 0.16
  23. Antonio Costanzo MD · 1 shared paper, 2019 · strength 0.10
  24. Sara Pusceddu · 1 shared paper, 2019 · strength 0.08
  25. Roberto Labianca · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.